Table 3.

Rates of common adverse events per 1000 patient-months of treatment by time-period from start of treatment with meloxicam.

Event¶	Number of events in month 1	Number of events in months 2–6	Rate† in month 1a	Rate† in months 2–6b	Arithmetic difference in rates	99% CI* for rate difference
Dyspepsia	435	379	28.3	8.5	19.8	16.1, 23.5
Respiratory tract infection	214	387	13.9	8.7	5.2	2.5, 7.9
Nausea, vomiting	189	136	12.3	3.1	9.2	6.8, 11.6
Pain abdomen	146	163	9.5	3.7	5.8	3.7, 8.0
Diarrhoea	118	110	7.7	2.5	5.2	3.3, 7.1
Dose increased	106	206	6.9	4.6	2.3	0.4, 4.2
Headache, migraine	81	82	5.3	1.8	3.4	1.8, 5.0
Minor surgery	75	100	4.9	2.2	2.6	1.1, 4.2
Hospital referrals no admission	74	144	4.8	3.2	1.6	0.0, 3.2
Oedema	74	96	4.8	2.2	2.7	1.1, 4.2
Dizziness	68	70	4.4	1.6	2.9	1.4, 4.3
Gastrointestinal unspecified	66	64	4.3	1.4	2.9	1.4, 4.3
Pain joint	57	143	3.7	3.2	0.5	−0.9, 1.9
Malaise, lassitude	56	81	3.6	1.8	1.8	0.5, 3.2
Constipation	56	57	3.6	1.3	2.4	1.0, 3.7
Hospital referral paramedical	51	55	3.3	1.2	2.1	0.8, 3.4
Cough	48	73	3.1	1.6	1.5	0.2, 2.7
Asthma, wheezing	48	46	3.1	1.0	2.1	0.9, 3.3
Rash	46	90	3.0	2.0	1.0	−0.3, 2.2
Hypertension‡	42	57	2.7	1.3	1.5	0.3, 2.6
Cardiac failure‡	24	29	1.6	0.7	0.9	0.0, 1.8
Palpitation‡	20	22	1.3	0.5	0.8	0.0, 1.6

^¶Ranked by number of events in months 1.

^†Rate is number of events in time period per 1000 patient-months of exposure in that time period.

^aNo. of patient months of exposure in month 1 was 15 382

^bNumber of patient months of exposure in month 2–6 was 44 581.

^*Confidence interval.

^‡There are other events occurring with a frequency in-between rash and these events, which are included in the table as the 99% confidence interval for the difference are greater than or equal to zero.